StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report published on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of EVOK stock opened at $1.25 on Friday. Evoke Pharma has a 52-week low of $0.92 and a 52-week high of $5.96. The company has a debt-to-equity ratio of 9.29, a quick ratio of 3.27 and a current ratio of 3.50. The firm has a market capitalization of $4.18 million, a PE ratio of -0.55 and a beta of 0.28. The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.48.
About Evoke Pharma
(Get Free Report)
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
Receive News & Ratings for Evoke Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evoke Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.
